China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed’s commitment to expanding its presence in the global obesity treatment market.
Technological Edge and Pipeline
Élancé Therapeutics will leverage Harbour BioMed’s proprietary HCAb-based bispecific antibody (BsAb) technology to advance the development of next-generation obesity treatments. The subsidiary boasts a product pipeline comprising multiple pre-clinical BsAb programs that utilize innovative mechanisms such as targeted hormone regulation and enhanced metabolic regulation to achieve therapeutic effects.
AI Platform Integration
Élancé will refine and expand the Hu-mAtrIx AI platform of Nona Biosciences, a wholly-owned subsidiary of Harbour BioMed, to support BsAb discovery. AI applications will guide antibody sequence discovery, enrichment, optimization, bispecific geometry design, and assessments of developability, immunogenicity, and pharmacokinetics (PK), as well as patient biomarker studies.-Fineline Info & Tech
Leave a Reply